190 related articles for article (PubMed ID: 33122623)
1. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
Khawaja H; Campbell A; Roberts JZ; Javadi A; O'Reilly P; McArt D; Allen WL; Majkut J; Rehm M; Bardelli A; Di Nicolantonio F; Scott CJ; Kennedy R; Vitale N; Harrison T; Sansom OJ; Longley DB; Evergren E; Van Schaeybroeck S
Cell Death Dis; 2020 Oct; 11(10):930. PubMed ID: 33122623
[TBL] [Abstract][Full Text] [Related]
2. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
3. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
4. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
5. H-Ras regulation of TRAIL death receptor mediated apoptosis.
Chen JJ; Bozza WP; Di X; Zhang Y; Hallett W; Zhang B
Oncotarget; 2014 Jul; 5(13):5125-37. PubMed ID: 25026275
[TBL] [Abstract][Full Text] [Related]
6. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.
Laguinge LM; Samara RN; Wang W; El-Deiry WS; Corner G; Augenlicht L; Mishra L; Jessup JM
Cancer Res; 2008 Feb; 68(3):909-17. PubMed ID: 18245494
[TBL] [Abstract][Full Text] [Related]
7. Inostamycin enhanced TRAIL-induced apoptosis through DR5 upregulation on the cell surface.
Yamamoto K; Makino M; Watanapokasin R; Tashiro E; Imoto M
J Antibiot (Tokyo); 2012 Jun; 65(6):295-300. PubMed ID: 22472572
[TBL] [Abstract][Full Text] [Related]
8. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
9. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
10. Activation and involvement of Ral GTPases in colorectal cancer.
Martin TD; Samuel JC; Routh ED; Der CJ; Yeh JJ
Cancer Res; 2011 Jan; 71(1):206-15. PubMed ID: 21199803
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
[TBL] [Abstract][Full Text] [Related]
12. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
[No Abstract] [Full Text] [Related]
13. Goniothalamin enhances TRAIL-induced apoptosis in colorectal cancer cells through DR5 upregulation and cFLIP downregulation.
Sophonnithiprasert T; Nilwarangkoon S; Nakamura Y; Watanapokasin R
Int J Oncol; 2015 Dec; 47(6):2188-96. PubMed ID: 26499766
[TBL] [Abstract][Full Text] [Related]
14. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
Fujiwara J; Sowa Y; Horinaka M; Koyama M; Wakada M; Miki T; Sakai T
Int J Oncol; 2012 May; 40(5):1483-91. PubMed ID: 22328338
[TBL] [Abstract][Full Text] [Related]
15. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Oh YT; Deng J; Yue P; Sun SY
Sci Rep; 2016 May; 6():26803. PubMed ID: 27222248
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5.
Hotta M; Sakatani T; Ishino K; Wada R; Kudo M; Yokoyama Y; Yamada T; Yoshida H; Naito Z
Biochem Biophys Res Commun; 2019 Nov; 519(4):824-831. PubMed ID: 31561852
[TBL] [Abstract][Full Text] [Related]
18. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
19. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.
Devetzi M; Kosmidou V; Vlassi M; Perysinakis I; Aggeli C; Choreftaki T; Zografos GN; Pintzas A
Sci Rep; 2016 Nov; 6():36532. PubMed ID: 27827395
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]